Reviewing Maplebear (NASDAQ:CART) and OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX) and Maplebear (NASDAQ:CART) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares OptimizeRx and Maplebear”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$88.18 million	1.03	-$17.57 million	($1.33)	-3.71
Maplebear	$3.30 billion	3.41	-$1.62 billion	$1.49	29.40

OptimizeRx has higher earnings, but lower revenue than Maplebear. OptimizeRx is trading at a lower price-to-earnings ratio than Maplebear, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 63.1% of Maplebear shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by company insiders. Comparatively, 36.0% of Maplebear shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares OptimizeRx and Maplebear’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-27.41%	-4.92%	-3.41%
Maplebear	13.37%	13.78%	10.51%

Volatility & Risk

OptimizeRx has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Maplebear has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for OptimizeRx and Maplebear, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	0	2	7	0	2.78
Maplebear	0	13	13	0	2.50

OptimizeRx currently has a consensus target price of $9.19, indicating a potential upside of 85.98%. Maplebear has a consensus target price of $47.14, indicating a potential upside of 7.59%. Given OptimizeRx’s stronger consensus rating and higher possible upside, research analysts clearly believe OptimizeRx is more favorable than Maplebear.

Summary

Maplebear beats OptimizeRx on 9 of the 14 factors compared between the two stocks.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About Maplebear

Maplebear Inc., doing business as Instacart, engages in the provision of online grocery shopping services to households in North America. It sells and delivers grocery products, as well as pickup services through a mobile application and website. It also operates virtual convenience stores; and provides software-as-a-service solutions to retailers. The company was incorporated in 2012 and is based in San Francisco, California.